109 related articles for article (PubMed ID: 18571543)
1. Cognitive outcome in treated patients with chronic neuronopathic Gaucher disease.
Goker-Alpan O; Wiggs EA; Eblan MJ; Benko W; Ziegler SG; Sidransky E; Schiffmann R
J Pediatr; 2008 Jul; 153(1):89-94. PubMed ID: 18571543
[TBL] [Abstract][Full Text] [Related]
2. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
3. The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.
Charrow J; Dulisse B; Grabowski GA; Weinreb NJ
Clin Genet; 2007 Mar; 71(3):205-11. PubMed ID: 17309642
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
El-Beshlawy A; Ragab L; Youssry I; Yakout K; El-Kiki H; Eid K; Mansour IM; Abd El-Hamid S; Yang M; Mistry PK
J Inherit Metab Dis; 2006 Feb; 29(1):92-8. PubMed ID: 16601874
[TBL] [Abstract][Full Text] [Related]
5. Histologic findings of femoral heads from patients with Gaucher disease treated with enzyme replacement.
Lebel E; Elstein D; Peleg A; Reinus C; Zimran A; Amir G
Am J Clin Pathol; 2013 Jul; 140(1):91-6. PubMed ID: 23765538
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
7. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
[TBL] [Abstract][Full Text] [Related]
8. Evoked potentials and neurocognitive functions in pediatric Egyptian Gaucher patients on enzyme replacement therapy: a single center experience.
Tantawy AA; Sherif EM; Adly AA; Hassanine S; Awad AH
J Inherit Metab Dis; 2013 Nov; 36(6):1025-37. PubMed ID: 23508695
[TBL] [Abstract][Full Text] [Related]
9. Mesenteric and Mediastinal Lymphadenopathy in Egyptian Children With Gaucher Disease Types 1 and 3 Treated With Enzyme Replacement Therapy.
Abdelwahab M; SeifEldien HM
J Pediatr Hematol Oncol; 2015 Jul; 37(5):e316-22. PubMed ID: 25521082
[TBL] [Abstract][Full Text] [Related]
10. [French results of enzyme replacement therapy in Gaucher's disease].
Schaison G; Caubel I; Belmatoug N; Billette de Villemeur T; Saudubray JM
Bull Acad Natl Med; 2002; 186(5):851-61; discussion 861-3. PubMed ID: 12412377
[TBL] [Abstract][Full Text] [Related]
11. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
12. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
Sechi A; Deroma L; Dardis A; Ciana G; Bertin N; Concolino D; Linari S; Perria C; Bembi B
Mol Genet Metab; 2014 Nov; 113(3):213-8. PubMed ID: 25127542
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
Fedida B; Touraine S; Stirnemann J; Belmatoug N; Laredo JD; Petrover D
Eur Radiol; 2015 Oct; 25(10):2969-75. PubMed ID: 25875285
[TBL] [Abstract][Full Text] [Related]
14. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
15. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
16. Delayed growth and puberty in patients with Gaucher disease type 1: natural history and effect of splenectomy and/or enzyme replacement therapy.
Kauli R; Zaizov R; Lazar L; Pertzelan A; Laron Z; Galatzer A; Phillip M; Yaniv Y; Cohen IJ
Isr Med Assoc J; 2000 Feb; 2(2):158-63. PubMed ID: 10804944
[TBL] [Abstract][Full Text] [Related]
17. Enzyme replacement therapy for Gaucher Disease: the only experience in Malaysia.
Chan LL; Lin HP
Med J Malaysia; 2002 Sep; 57(3):348-52. PubMed ID: 12440275
[TBL] [Abstract][Full Text] [Related]
18. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
[TBL] [Abstract][Full Text] [Related]
19. Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage?
Brunel-Guitton C; Rivard GE; Galipeau J; Alos N; Miron MC; Therrien R; Mitchell G; Lapierre G; Lambert M
Mol Genet Metab; 2009 Feb; 96(2):73-6. PubMed ID: 19083253
[TBL] [Abstract][Full Text] [Related]
20. Type I Gaucher disease in children with and without enzyme therapy.
Dweck A; Abrahamov A; Hadas-Halpern I; Bdolach-Avram T; Zimran A; Elstein D
Pediatr Hematol Oncol; 2002 Sep; 19(6):389-97. PubMed ID: 12186361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
